Previous 10 |
- In Preclinical Testing, Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time - Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and...
Odonate Therapeutics (NASDAQ: ODT ): Q4 GAAP EPS of -$1.17 misses by $0.07. More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2018. As of...
Shares of Odonate Therapeutics ( ODT ) have lost 45% of their value since the company's December 2017 IPO was done at a price point of $24 per share. Over the past three months, the stock has lost a quarter of its value. Regardless of weak technicals, the fundamental story seems quite intr...
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signif...
The enemy is anybody who's going to get you killed, no matter which side he is on. " - Joseph Heller, Catch-22 I had a question from a Seeking Alpha follower last week on a company that has not been public for at least a year and a half yet. I usually leave IPOs alone until they have been...
Insider buying increased last week with insiders purchasing $66.26 million of stock compared to $45.76 million in the week prior. Selling almost doubled with insiders selling $500.08 million of stock last week compared to $257.89 million in the week prior. Sell/Buy Ratio: The insider Sell/...
Insider buying declined sharply last week with insiders purchasing $43.43 million of stock compared to $200.17 million in the week prior. Selling on the other hand increased with insiders selling $1.95 billion of stock last week compared to $1.7 billion in the week prior. Sell/Buy Ratio: T...
News, Short Squeeze, Breakout and More Instantly...
Odonate Therapeutics Inc. Company Name:
ODT Stock Symbol:
NASDAQ Market:
Odonate Therapeutics Inc. Website:
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the c...
ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODT ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, L...
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company’s previously announced decision to discontinue the deve...